Sexually Transmitted Diseases, Viral News

Sexually Transmitted Diseases, Viral	Welcome, Profile Billing Logout

«1 2...36 37 38 39 404142 43 44 45 46...49 50 »

||||||||||  Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P3 trial:  PHI04: Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet (clinicaltrials.gov) -  Sep 25, 2012
P3, N=30, Recruiting,  Sponsor: Mehri McKellar, MD

||||||||||  emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion:  FEM-PrEP (Truvada (clinicaltrials.gov) -  Sep 25, 2012
P3, N=2120, Completed,  Sponsor: FHI 360
Active, not recruiting --> Completed

|||||||||| Trial completion: Community Intervention Trial for Youth (CITY) Study (clinicaltrials.gov) - Sep 25, 2012
P2/3, N=12000, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users (clinicaltrials.gov) - Sep 25, 2012
P2/3, N=1400, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: Parents Matter!: Interventions to Promote Effective Parent-Child Communication (clinicaltrials.gov) - Sep 25, 2012
P1, N=2210, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: Video-based Intervention Study to Prevent HIV/Sexually Transmitted Diseases (STDs) Among STD Clinic Patients (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=45000, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion, Adherence: Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=180, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| New P3 trial: Positive Change Agents Program-Tanzania (Evaluation) (clinicaltrials.gov) - Sep 24, 2012
P3, N=1296, Enrolling by invitation, Sponsor: Harvard School of Public Health

|||||||||| Trial completion: HIV Vaccine Study in HIV Positive Patients (clinicaltrials.gov) - Sep 24, 2012
P1, N=54, Completed, Sponsor: PepTcell Limited
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Enrollment change: Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants (clinicaltrials.gov) - Sep 23, 2012
P1, N=185, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed N=32 --> 185

||||||||||  Edurant (rilpivirine) / J&J
New P4 trial:  A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection (clinicaltrials.gov) -  Sep 23, 2012
P4, N=0, Withdrawn,  Sponsor: Janssen Pharmaceutica

||||||||||  Leukine (sargramostim) / Partner Therap
Trial termination:  IMIRC1003: Novel Interventions in HIV-1 Infection (clinicaltrials.gov) -  Sep 19, 2012
P1, N=12, Terminated,  Sponsor: Imperial College London
N=32 --> 185 Active, not recruiting --> Terminated; Data from the 12 patients recruited has now been analysed, and it has been determined that it is sufficient to meet the study objectives.

||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial completion:  Evaluation of the Bioequivalence of a Combined Formulated Tablet (clinicaltrials.gov) -  Sep 19, 2012
P1, N=66, Completed,  Sponsor: ViiV Healthcare
Active, not recruiting --> Terminated; Data from the 12 patients recruited has now been analysed, and it has been determined that it is sufficient to meet the study objectives. Active, not recruiting --> Completed

|||||||||| Enrollment change: Sex, Aging and Antiretroviral Pharmacokinetics (clinicaltrials.gov) - Sep 17, 2012
P=N/A, N=11, Completed, Sponsor: Kristine Patterson, MD
Active, not recruiting --> Completed N=42 --> 11

|||||||||| Trial completion: Sex, Aging and Antiretroviral Pharmacokinetics (clinicaltrials.gov) - Sep 17, 2012
P=N/A, N=11, Completed, Sponsor: Kristine Patterson, MD
N=42 --> 11 Recruiting --> Completed

|||||||||| Trial completion: Directly Observed Therapy for HIV Infected Adolescents (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=24, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  didanosine / Generic mfg.
Trial completion:  The Adult Antiretroviral Treatment and Resistance Study (Tshepo) (clinicaltrials.gov) -  Sep 13, 2012
P3, N=650, Completed,  Sponsor: Harvard School of Public Health
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  metformin / Generic mfg.
Enrollment change:  Lifestyle Modification and Metformin Use in the Treatment of HIV (clinicaltrials.gov) -  Sep 12, 2012
P=N/A, N=50, Completed,  Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed N=200 --> 50

||||||||||  Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
New P2 trial:  Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults (clinicaltrials.gov) -  Sep 12, 2012
P2, N=420, Recruiting,  Sponsor: University of Colorado, Denver

||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed:  VIKING-3: A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. (clinicaltrials.gov) -  Sep 12, 2012
P3, N=175, Active, not recruiting,  Sponsor: ViiV Healthcare
N=200 --> 50 Recruiting --> Active, not recruiting

|||||||||| Trial completion: Trial of Zinc and HIV Progression in Children (clinicaltrials.gov) - Sep 12, 2012
P3, N=440, Completed, Sponsor: Harvard School of Public Health
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  metformin / Generic mfg.
Trial completion:  Lifestyle Modification and Metformin Use in the Treatment of HIV (clinicaltrials.gov) -  Sep 12, 2012
P=N/A, N=50, Completed,  Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Foclivia (adjuvanted egg-based influenza A (H5N1) vaccine) / CSL Behring
Enrollment change:  Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection (clinicaltrials.gov) -  Sep 11, 2012
P3, N=154, Completed,  Sponsor: Chiltern Pesquisa Clinica Ltda
Active, not recruiting --> Completed N=340 --> 154

||||||||||  Foclivia (adjuvanted egg-based influenza A (H5N1) vaccine) / CSL Behring
Trial completion:  Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection (clinicaltrials.gov) -  Sep 11, 2012
P3, N=154, Completed,  Sponsor: Chiltern Pesquisa Clinica Ltda
N=340 --> 154 Active, not recruiting --> Completed

|||||||||| Trial initiation date: Improving Uptake of Early Infant Diagnosis of HIV for the Prevention of Mother-to-child Transmission of HIV (clinicaltrials.gov) - Sep 10, 2012
P=N/A, N=388, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Initiation date: Oct 2011 --> Apr 2012

|||||||||| Trial termination: Home-based AIDS Care Project (clinicaltrials.gov) - Sep 9, 2012
P=N/A, N=1000, Terminated, Sponsor: Centers for Disease Control and Prevention
Initiation date: Oct 2011 --> Apr 2012 Recruiting --> Terminated; Terminated by IRB for non-compliance with human subject regulations.

|||||||||| Enrollment change: Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center (clinicaltrials.gov) - Sep 9, 2012
P=N/A, N=33, Completed, Sponsor: Centers for Disease Control and Prevention
Recruiting --> Terminated; Terminated by IRB for non-compliance with human subject regulations. N=176 --> 33

|||||||||| Clinical: SAHAPS: Efficacy of HIV Post-Test Support for ANC in South Africa (clinicaltrials.gov) - Sep 9, 2012
P=N/A, N=1500, Completed, Sponsor: University of North Carolina, Chapel Hill

|||||||||| Trial completion: Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center (clinicaltrials.gov) - Sep 9, 2012
P=N/A, N=33, Completed, Sponsor: Centers for Disease Control and Prevention
N=176 --> 33 Recruiting --> Completed

|||||||||| Trial completion: Lay Health Advisors for Sexually Transmitted Disease Prevention (clinicaltrials.gov) - Sep 9, 2012
P1/2, N=354, Completed, Sponsor: Centers for Disease Control and Prevention
Recruiting --> Completed Recruiting --> Completed

||||||||||  acyclovir / Generic mfg.
Trial completion:  Episodic Acyclovir Therapy for Genital Ulcers (clinicaltrials.gov) -  Sep 9, 2012
P2/3, N=613, Completed,  Sponsor: Centers for Disease Control and Prevention
Recruiting --> Completed Recruiting --> Completed

|||||||||| Trial completion: HIP: HIV Intervention for Providers (clinicaltrials.gov) - Sep 9, 2012
P2, N=50, Completed, Sponsor: Centers for Disease Control and Prevention
Recruiting --> Completed Recruiting --> Completed

||||||||||  Isentress (raltegravir) / Merck (MSD)
Enrollment change:  Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women (clinicaltrials.gov) -  Sep 6, 2012
P=N/A, N=28, Completed,  Sponsor: University of Rochester
Recruiting --> Completed N=20 --> 28

||||||||||  Isentress (raltegravir) / Merck (MSD)
Trial completion:  Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women (clinicaltrials.gov) -  Sep 6, 2012
P=N/A, N=28, Completed,  Sponsor: University of Rochester
N=20 --> 28 Recruiting --> Completed

||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed:  SPRING-2: A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily (clinicaltrials.gov) -  Sep 5, 2012
P3, N=788, Active, not recruiting,  Sponsor: ViiV Healthcare
Recruiting --> Completed Completed --> Active, not recruiting

||||||||||  Isentress (raltegravir) / Merck (MSD)
New P4 trial, Adverse events:  TaISENWITCH: Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study (clinicaltrials.gov) -  Sep 4, 2012
P4, N=120, Recruiting,  Sponsor: Lin, Hsi-Hsun, M.D.

||||||||||  Farydak (panobinostat) / Secura Bio
New P1/2 trial, Epigenetic controller:  CLEAR: Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART (clinicaltrials.gov) -  Sep 4, 2012
P1/2, N=15, Completed,  Sponsor: University of Aarhus

|||||||||| Clinical: Gut Associated Lymphatic Tissue (GALT) in HIV (Human Immunodeficiency Virus)- Infected Patients (clinicaltrials.gov) - Sep 3, 2012
P=N/A, N=30, Recruiting, Sponsor: Clara Lehmann

||||||||||  HIV vaccine vCP1521 / Sanofi, ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion:  HIV Vaccine Trial in Thai Adults (clinicaltrials.gov) -  Sep 3, 2012
P3, N=16402, Completed,  Sponsor: U.S. Army Medical Research and Materiel Command
Completed --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Trial completion: Maintaining HIV Prevention Gains in Female Adolescents (clinicaltrials.gov) - Sep 3, 2012
P2, N=640, Completed, Sponsor: University of Rochester
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  efavirenz / Generic mfg.
Enrollment closed:  Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805) (clinicaltrials.gov) -  Aug 30, 2012
P4, N=90, Active, not recruiting,  Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Isentress (raltegravir) / Merck (MSD)
Enrollment closed:  RADAR: Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients (clinicaltrials.gov) -  Aug 30, 2012
P4, N=80, Active, not recruiting,  Sponsor: Dallas VA Medical Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

|||||||||| New P4 trial: Pilot Study of Diflunisal in HIV-infected Adults (clinicaltrials.gov) - Aug 28, 2012
P4, N=20, Recruiting, Sponsor: University of British Columbia

||||||||||  acyclovir / Generic mfg.
Enrollment change:  Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda (clinicaltrials.gov) -  Aug 27, 2012
P2, N=440, Completed,  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting N=1320 --> 440

||||||||||  Stamaril (yellow fever vaccine) / Sanofi
Enrollment change:  The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. (clinicaltrials.gov) -  Aug 23, 2012
P3, N=71, Active, not recruiting,  Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
N=1320 --> 440 N=57 --> 71

||||||||||  nevirapine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lamivudine/zidovudine / Generic mfg.
Enrollment change:  Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT) (clinicaltrials.gov) -  Aug 23, 2012
P=N/A, N=566, Completed,  Sponsor: Rigshospitalet, Denmark
N=57 --> 71 N=450 --> 566

||||||||||  Stamaril (yellow fever vaccine) / Sanofi
Enrollment closed:  The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. (clinicaltrials.gov) -  Aug 23, 2012
P3, N=71, Active, not recruiting,  Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
N=450 --> 566 Completed --> Active, not recruiting

||||||||||  nevirapine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lamivudine/zidovudine / Generic mfg.
Trial completion:  Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT) (clinicaltrials.gov) -  Aug 23, 2012
P=N/A, N=566, Completed,  Sponsor: Rigshospitalet, Denmark
Completed --> Active, not recruiting Recruiting --> Completed

|||||||||| Enrollment change: Sleep Quality and Presence of Sleep Disordered Breathing (clinicaltrials.gov) - Aug 22, 2012
P=N/A, N=74, Completed, Sponsor: University of Florida
Recruiting --> Completed N=200 --> 74

|||||||||| Trial completion: Sleep Quality and Presence of Sleep Disordered Breathing (clinicaltrials.gov) - Aug 22, 2012
P=N/A, N=74, Completed, Sponsor: University of Florida
N=200 --> 74 Recruiting --> Completed



	Diseases Companies Products Productz Mechanisms of Action Sites